IART at a glance
INTEGRA LIFESCIENCES HOLDINGS CORP (IART, SEC CIK 917520) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on July 29, 2026, an 8-K current report on October 2, 2026 and Form 4 insider filings as recently as September 4, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), INTEGRA LIFESCIENCES HOLDINGS CORP (IART) reported revenue of $1.6 billion (up 1.5% from FY2024) and a net loss of $516.5 million. Diluted EPS was -$6.74.
- As of June 30, 2026, 31 institutional investment managers tracked by SignalX reported holding INTEGRA LIFESCIENCES HOLDINGS CORP (IART) shares worth $682.6 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $1.6B
- +1.5% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 31 funds
- $682.6M · +2 vs prior quarter
- Latest 8-K
- Sep 8, 2026
- Item 7.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Filing excerpt truncates after executive summary; quarterly revenue and YoY comparison unavailable
- Profitability margins and actual percentage changes unavailable in provided text
- Segment mix: Specialty Surgery approximately 70% of revenue; Tissue Reconstruction about 30%
- Braintree facility operational June 2026; SurgiMend relaunch planned fourth quarter 2026
- Cincinnati flooding caused operational disruptions; financial impact and insurance recoveries remain under assessment
Risk Factors
- No material changes to 10-K risk factors for year ended December 31, 2025
- Carried-forward regulatory and compliance risks remain unchanged from the 2025 10-K
- Carried-forward operational and competitive risks remain unchanged from the 2025 10-K
- Carried-forward liquidity, debt, currency, and concentration risks remain unchanged from the 2025 10-K
AI summary of the IART 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Updated investor presentation supports refinancing of Integra’s outstanding senior credit facility in 2026
- Materials may be used with existing and prospective lenders during refinancing discussions
Item 2.02: Results of Operations and Financial Condition
- Non-GAAP framework covers organic revenue, adjusted EBITDA, adjusted EPS, margins, and net debt for quarter ended June 30, 2026
- Goodwill impairment reflects heightened risks from tariffs, quality, operational, and supply issues affecting market capitalization
Item EX-99.1: Item EX-99.1
- Q2 revenue $418.8M, up 0.8% reported and 0.7% organic, signaling modest underlying growth
- Adjusted EPS $0.56 versus $0.45, while GAAP EPS improved to $0.06 from $(6.31) after prior-year impairment
AI summaries of IART 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for IART
Don't miss the next IART filing
- Alerts as it files. A push when IART files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut IART, by share count.
- Ask anything. An AI agent that reads every IART filing and answers with sources.
IART alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Veillon-Berteloot Chantal | F | Sep 1, 2026 | 1,455 | $16.62 |
| Knight Lea Daniels | F | Jul 3, 2026 | 5,226 | $18.05 |
| Singh Harvinder | A | Jul 1, 2026 | 5,590 | - |
| Mosebrook Jeffrey | F | Jul 1, 2026 | 937 | $17.89 |
| DAVIS ROBERT T. JR. | A | Jul 1, 2026 | 11,180 | - |
| McBreen Michael J. | A | Jun 1, 2026 | 60,372 | - |
| McBreen Michael J. | A | Jun 1, 2026 | 31,909 | - |
| BRADLEY KEITH | F | May 9, 2026 | 882 | $13.92 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $1.6B | $1.6B |
| Operating Income | - | $28.4M | -$493.4M |
| Net Income | $67.7M | -$6.9M | -$516.5M |
| Op. Margin | - | 1.8% | -30.2% |
| Net Margin | - | -0.4% | -31.6% |
| Balance Sheet | |||
| Total Assets | $3.8B | $4.0B | $3.6B |
| Equity | - | $1.5B | $1.0B |
| ROE | - | -0.4% | -49.5% |
| Per Share | |||
| EPS | $0.84 | $-0.09 | $-6.74 |
| Cash Flow | |||
| Operating CF | - | $129.4M | $50.4M |
| CapEx | $66.9M | $104.4M | $81.4M |
Source: XBRL data in INTEGRA LIFESCIENCES HOLDINGS CORP (IART)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate IART share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 31 | $682.6M |
| Q1 2026 | 29 | $352.3M |
| Q4 2025 | 28 | $463.0M |
| Q3 2025 | 28 | $542.9M |
| Q2 2025 | 28 | $471.8M |
| Q1 2025 | 25 | $604.0M |
| Q4 2024 | 20 | $419.1M |
| Q3 2024 | 18 | $210.6M |
- Millennium Management+816.9K (+131%)
- BlackRock+364.9K (+4%)
- Invesco Ltd+263.8K (+8%)
- AQR Capital Management+122.6K (+90%)
- D.E. Shaw & Co+117.8K (+30%)
- Dimensional Fund Advisors−558.3K (-20%)
- Goldman Sachs Group−403.0K (-21%)
- JPMorgan Chase & Co−178.0K (-45%)
- Bank of America Corp−85.3K (-6%)
- Two Sigma Investments−27.8K (-13%)
- Franklin Resources+230.6K
- Mangrove Partners+42.8K
- Renaissance Technologies LLC+10.5K
- Citadel Advisors LLC−476.7K
Source: 13F-HR filings on SEC EDGAR (aggregated from 207 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
IART filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Oct 2, 2026 | - | - | - |
| 8-K | Sep 8, 2026 | - | Analysis | - |
| 4 | Sep 4, 2026 | - | - | - |
| SC 13G | Jul 31, 2026 | - | - | |
| 10-Q | Jul 29, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jul 29, 2026 | - | Analysis | - |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jun 3, 2026 | - | - | |
| SC 13G | May 15, 2026 | - | - | |
| 4 | May 11, 2026 | - | - | |
| 4 | May 11, 2026 | - | - | |
| 4 | May 11, 2026 | - | - | |
| 4 | May 11, 2026 | - | - | |
| 4 | May 11, 2026 | - | - | |
| 4 | May 11, 2026 | - | - | |
| 8-K | May 8, 2026 | - | Analysis | |
| 8-K | May 5, 2026 | - | Analysis | - |
| 8-K | May 5, 2026 | - | Analysis | - |
| 10-Q | May 5, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | Apr 15, 2026 | - | Analysis | - |
| 4 | Mar 12, 2026 | - | - | - |
| 4 | Mar 12, 2026 | - | - | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
IART SEC filings: frequently asked questions
Which institutions hold IART stock?
As of June 30, 2026, the largest INTEGRA LIFESCIENCES HOLDINGS CORP (IART) holders among the 13F filers tracked by SignalX were BlackRock ($191.9 million), Invesco Ltd ($67.3 million), Vanguard Portfolio Management LLC ($67.2 million), Morgan Stanley ($64.5 million), State Street Corp ($52.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was IART's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), INTEGRA LIFESCIENCES HOLDINGS CORP (IART) reported revenue of $1.6 billion (up 1.5% from FY2024) and a net loss of $516.5 million. Diluted EPS was -$6.74. The figures come from the XBRL data in the 10-K.
What did IART report in its latest 8-K?
INTEGRA LIFESCIENCES HOLDINGS CORP (IART) filed an 8-K on September 8, 2026 reporting Item 7.01 (Regulation FD Disclosure). Updated investor presentation supports refinancing of Integra’s outstanding senior credit facility in 2026.
What are the latest IART SEC filings?
INTEGRA LIFESCIENCES HOLDINGS CORP (IART) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on July 29, 2026, an 8-K current report on October 2, 2026 and a Form 4 insider filing on September 4, 2026.
What is IART's SEC CIK number?
INTEGRA LIFESCIENCES HOLDINGS CORP (IART)'s SEC Central Index Key (CIK) is 917520. EDGAR lists every IART filing under that number.
Ask anything about IART
The research agent reads IART's filings, financials, insider trades and 13F holders, then answers with sources.